☆ 4.6 Article

Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study

FRONTIERS IN NEUROLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Immunology

Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study

Natacha Madelon et al.

Summary: Despite impaired humoral responses, patients on anti-CD20 treatment who are at risk for severe COVID-19 can mount potent T-cell responses to mRNA COVID-19 vaccines. This could play an important role in the reduction of complications of COVID-19.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Clinical Neurology

Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study

Luigi Pontieri et al.

Summary: This study evaluated the real-world effectiveness and safety of ocrelizumab treatment for multiple sclerosis (MS) patients in Denmark. The results showed that most patients experienced clinical stabilization and had a favorable adverse event profile consistent with previous clinical trials. Ocrelizumab was well tolerated with minimal side effects reported in only 10% of patients.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

Add to Collection

Review Clinical Neurology

Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis

Manila Hada et al.

Summary: This study reviewed the risk of SARS-CoV-2 infection and severe COVID-19 outcomes in multiple sclerosis (MS) patients treated with approved therapies in the United States. The findings suggest that MS patients treated with anti-CD20 monoclonal antibodies may be at increased risk for severe COVID-19. Further monitoring is warranted due to the potential implications for public health, especially in subpopulations with impaired response to COVID-19 vaccines.

NEUROLOGICAL SCIENCES (2022)

Add to Collection

Article Clinical Neurology

Humoral- and T-Cell Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies

Carla Tortorella et al.

Summary: This study evaluated the immune-specific response after full SARS-CoV-2 vaccination in patients with multiple sclerosis (MS) treated with different disease-modifying drugs. The results showed that mRNA vaccines induced both humoral and cell-mediated specific immune responses against viral spike proteins in the majority of patients with MS. These findings have important implications for promoting vaccination in all MS patients.

NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab

Livnat Brill et al.

Summary: This study aimed to evaluate the humoral and cellular response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with B-cell depletion, particularly those who had a weak response to initial vaccination. The study found that the antibody titers did not increase in patients who had a weak or no response after the initial vaccination following the third vaccine dose. However, in healthy controls and MS patients treated with B-cell depletion, cellular response significantly increased after the third dose of the vaccine.

ANNALS OF NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab

Saskia Raeuber et al.

Summary: In MS patients treated with OCR, the humoral immune response to SARS-CoV-2 vaccination is attenuated while the T cell response is preserved. Monitoring of peripheral B cell counts may facilitate individualized treatment regimens and determine the optimal timing for vaccination.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

Add to Collection

Article Clinical Neurology

Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab

Natacha Madelon et al.

Summary: This study aimed to investigate T-cell responses to the Omicron spike protein in patients with multiple sclerosis (MS) treated with anti-CD20 therapy before and after a third mRNA COVID-19 vaccination. The results showed that the third dose enhanced T-cell responses to all variants, suggesting that COVID-19 vaccination may protect patients taking B-cell-depleting drugs against severe complications from infection.

JAMA NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: Effects of disease modifying therapies

Mario Habek et al.

Summary: In patients with multiple sclerosis, those treated with ocrelizumab are less likely to develop humoral immunity after COVID-19 recovery or vaccination, but there is no difference in cellular immunity compared to other treatment groups. This suggests that pwMS still have a certain level of cellular immune protection even when receiving B-cell depleting therapy.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Add to Collection

Review Clinical Neurology

A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications

Larissa Hauer et al.

Summary: MS is a chronic autoimmune disorder that often comes with various comorbidities. These comorbidities can affect the diagnosis and disease course of MS, highlighting the importance of understanding and managing them for improved patient outcomes.

JOURNAL OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Maria P. Sormani et al.

Summary: This study assessed the impact of immunosuppressive and immunomodulatory therapies on the severity of COVID-19 in people with multiple sclerosis. Therapy with an anti-CD20 agent and recent use of methylprednisolone were associated with increased risk of severe COVID-19.

ANNALS OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis

Steve Simpson-Yap et al.

Summary: Using data from 12 sources in 28 countries, this study examined the characteristics of COVID-19 severity in people with MS, particularly those taking immunosuppressive therapies. The results showed that older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Additionally, rituximab was consistently associated with increased risk of hospitalization, ICU admission, and need for ventilation, while ocrelizumab was mainly associated with hospitalization and ICU admission.

NEUROLOGY (2021)

Add to Collection

Article Health Care Sciences & Services

Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in US commercial claims data

Natalie J. Engmann et al.

Summary: In the United States, patients initiating OCR showed superior persistence and adherence at 12 and 18 months of follow-up compared to those initiating other MS DMTs. Long-term persistence and adherence should be monitored as real-world experience with OCR accumulates.

JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2021)

Add to Collection

Article Clinical Neurology

COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies

Anthony T. Reder et al.

Summary: The study revealed that comorbidities, obesity, and Black/African ancestry were major risk factors for SARS-CoV-2 infection in patients with multiple sclerosis (PwMS). It also found that interferons and glatiramer acetate were associated with reduced COVID-19 risk, while anti-CD20 therapies were linked to increased risk within the treated MS cohort.

CNS DRUGS (2021)

Add to Collection

Article Clinical Neurology

Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis

Amber Salter et al.

Summary: This study examined outcomes and risk factors associated with COVID-19 clinical severity in a large, diverse cohort of North American patients with multiple sclerosis. The study found that ambulatory disability, older age, male sex, Black race, cardiovascular comorbidities, and recent corticosteroid use were associated with increased odds of worse clinical severity in MS patients with COVID-19. Knowledge of these risk factors may help improve the treatment and monitoring of these patients.

JAMA NEUROLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

Sokratis A. Apostolidis et al.

Summary: Patients with multiple sclerosis on anti-CD20 monotherapy exhibit significantly reduced SARS-CoV-2-specific antibodies and memory B cells, while CD4(+) and CD8(+) T cells are robustly activated compared to healthy controls after receiving BNT162b2 or mRNA-1273 mRNA vaccination.

NATURE MEDICINE (2021)

Add to Collection

Article Clinical Neurology

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis

Stephen L. Hauser et al.

Summary: This study reports the safety of ocrelizumab treatment for up to 7 years in patients with multiple sclerosis, showing a consistent and manageable safety profile without emerging safety concerns. The rates of the most common serious adverse events, including serious infections and malignancies, were consistent with epidemiologic data ranges. Additionally, long-term, continuous treatment with ocrelizumab was associated with a favorable safety profile in a heterogeneous multiple sclerosis population.

NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab

Livnat Brill et al.

Summary: Patients with MS treated with ocrelizumab showed comparable SARS-CoV-2-specific T-cell responses with healthy controls but lower antibody response following vaccination. This study provides reassurance regarding the potential role of T cells in protection from severe disease and will aid in the development of consensus guidelines for MS treatment during the COVID-19 pandemic.

JAMA NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study

Kyle Smoot et al.

Summary: The study aimed to evaluate the safety and treatment outcomes of ocrelizumab in a community-based MS population. Results showed that ocrelizumab effectively controlled relapse risk and disability worsening, but infections leading to hospitalizations, especially in older and disabled patients, remained a concern despite a low discontinuation rate of the treatment.

BMJ NEUROLOGY OPEN (2021)

Add to Collection

Article Clinical Neurology

Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol

Petra Dirks et al.

BMC NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)

Helmut Butzkueven et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)

Add to Collection

Article Medicine, General & Internal

Health-Related Quality of Life and the Relationship to Treatment Satisfaction in Patients with Multiple Sclerosis: Insights from a Large Observational Study

Dirk Schriefer et al.

PATIENT PREFERENCE AND ADHERENCE (2020)

Add to Collection

Article Clinical Neurology

Ocrelizumab initiation in patients with MS A multicenter observational study

Erik Ellwardt et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)

Add to Collection

Review Pharmacology & Pharmacy

Long-term drug treatment in multiple sclerosis: safety success and concerns

Dejan Jakimovski et al.

EXPERT OPINION ON DRUG SAFETY (2020)

Add to Collection

Letter Clinical Neurology

COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series

Richard Hughes et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

Add to Collection

Article Clinical Neurology

Data Collection in Multiple Sclerosis: The MSDS Approach

Tjalf Ziemssen et al.

FRONTIERS IN NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Five years of ocrelizumab in relapsing multiple sclerosis OPERA studies open-label extension

Stephen L. Hauser et al.

NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis The VELOCE study

Amit Bar-Or et al.

NEUROLOGY (2020)

Add to Collection

Review Clinical Neurology

Comorbidity in Multiple Sclerosis

Melinda Magyari et al.

FRONTIERS IN NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

Jerry S. Wolinsky et al.

LANCET NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Multiple sclerosis and cancer incidence: A Danish nationwide cohort study

M. Norgaard et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)

Add to Collection

Article Clinical Neurology

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA

Tjalf Ziemssen et al.

NEUROTHERAPEUTICS (2018)

Add to Collection

Article Pharmacology & Pharmacy

Improving multiple sclerosis management and collecting safety information in the real world: the MSDS3D software approach

Rocco Haase et al.

EXPERT OPINION ON DRUG SAFETY (2018)

Add to Collection

Article Clinical Neurology

Infection-related health care utilization among people with and without multiple sclerosis

Jose M. A. Wijnands et al.

MULTIPLE SCLEROSIS JOURNAL (2017)

Add to Collection

Article Clinical Neurology

Infection-related health care utilization among people with and without multiple sclerosis

Jose M. A. Wijnands et al.

MULTIPLE SCLEROSIS JOURNAL (2017)

Add to Collection

Article Medicine, General & Internal

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

S. L. Hauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

X. Montalban et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

The importance of collecting structured clinical information on multiple sclerosis

Tjalf Ziemssen et al.

BMC MEDICINE (2016)

Add to Collection

Article Health Care Sciences & Services

Increased Relapse Activity for Multiple Sclerosis Natalizumab Users Who Become Nonpersistent: A Retrospective Study

R. Brett McQueen et al.

JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2015)

Add to Collection

Review Medicine, General & Internal

Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature

Luis Lizan et al.

PATIENT PREFERENCE AND ADHERENCE (2014)

Add to Collection

Review Clinical Neurology

PML diagnostic criteria Consensus statement from the AAN Neuroinfectious Disease Section

Joseph R. Berger et al.

NEUROLOGY (2013)

Add to Collection

© Peeref 2019-2024. All rights reserved.